AntibioticDB

Highest development stage: Phase 1

Development status: Active

Gram-negative activity

Mechanism of Action/Target pathogen: Infections caused by MDR Gram- negative pathogens including enterics and Pseudomonas harbouring metallo-β-lactamases (MBL) as well as carbapenem-hydrolysing (CHDL) Class D β-lactamases in Acinetobacter spp and Klebsiella.

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10874

Citation (1): https://aac.asm.org/content/61/6/e02529-16

Citation (2): https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Safety+and+pharmacokinetics+of+multiple+ascending+doses+of+WCK+5107+%28zidebactam%29+and+WCK+5222+%28cefepime+and+zidebactam%29&id=2173&L=0&x=0&y=0

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/77846445

Zidebactam, WCK 5107

Beta-lactamase inhibitor

Wockhardt

2017